Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 11/20 | 0.43 |
| ▸ | NMT2 | O60551 | 10/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668934 | 0.94 | NPY4R (0.38) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL20889009 | 0.93 | NMT1 (0.41) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL18910973 | 0.91 | NMT1 (0.40) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL22668929 | 0.91 | PTGS1 (0.44) | NMT1NMT2PTGS1PTGS2NPY4R | |
| SCHEMBL20889000 | 0.91 | NMT1 (0.46) | NMT1NMT2TLR2NPY4RNPY1R | |
| SCHEMBL23436462 | 0.91 | NMT1 (0.46) | NMT1NMT2TLR2NPY4RNPY1R | |
| SCHEMBL19681474 | 0.90 | NPY5R (0.39) | NMT1NMT2PTGS1PTGS2NPY4R | |
| SCHEMBL17722904 | 0.90 | NMT1 (0.45) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL20935183 | 0.89 | NPY4R (0.36) | NMT1NMT2TLR2PTGS1PTGS2 | |
| SCHEMBL22267878 | 0.88 | FAP (0.37) | NMT1NMT2PTGS1PTGS2NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2018-08-09 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | NMT1 248/4885NMT2 325/4885TLR2 4063/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | NMT1 1554/4885NMT2 1665/4885TLR2 840/4885 |
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | NMT1 1493/4885NMT2 2096/4885TLR2 3328/4885 |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | NMT1 1104/4885NMT2 1659/4885TLR2 4752/4885 |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | NMT1 1104/4885NMT2 1659/4885TLR2 4752/4885 |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | NMT1 1190/4885NMT2 1454/4885TLR2 1416/4885 |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | NMT1 1104/4885NMT2 1659/4885TLR2 4752/4885 |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | NMT1 131/4885NMT2 140/4885TLR2 3413/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | NMT1 131/4885NMT2 140/4885TLR2 3413/4885 |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.